Related Experiment Video
Updated: May 17, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
[Expression and significance of Raf kinase inhibitory protein in lung cancer]
1Department of Internal Medicine, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Background:
Raf kinase inhibitory protein (RKIP) belongs to the phosphatidylethanolamine binding protein family. RKIP is an endogenous inhibitor of the ERK/MAPK, NF-κΒ, and G protein-coupled receptor signaling pathways. This study aims to investigate the expression of RKIP in non-small cell lung cancer (NSCLC) and to determine the association of RKIP expression with the clinicopathologic features of NSCLC.
Methods:
Reverse transcription-polymerase chain reaction, Western blot, and immunohistochemistry were used to detect RKIP expression in 83 specimens with NSCLC and normal lung tissues and to analyze the association of RKIP expression with the clinicopathologic features of NSCLC. All cases were confirmed by pathological diagnosis, and primary tumors were not found at other sites. No medical records of preoperative radiotherapy, chemotherapy, and immunotherapy were found in the groups.
Results:
RKIP expression was down-regulated significantly in NSCLC compared with adjacent cancer tissues (P<0.05). It was associated with differentiation, pathological tumor-node-metastasis stage, survival time, and lympho invasion (P<0.05) but not with gender, smoking status, age, tumor size, and histologic type (P>0.05).
Conclusions:
The deficiency of RKIP expression is positively correlated with carcinogenesis and invasion metastasis of NSCLC. RKIP is a potential marker and target for clinic therapy.
Insights
Down-regulation of Raf kinase inhibitory protein (RKIP) in non-small cell lung cancer (NSCLC) correlates with tumor progression and invasion. RKIP deficiency indicates a potential therapeutic target for NSCLC.
Area of Science:
- Molecular biology
- Oncology
- Biochemistry
Context:
- Raf kinase inhibitory protein (RKIP) is a key regulator of cellular signaling pathways, including ERK/MAPK and NF-κB.
- Dysregulation of RKIP has been implicated in various cancers, but its role in non-small cell lung cancer (NSCLC) requires further elucidation.
Purpose:
- To investigate the expression levels of RKIP in NSCLC tissues.
- To determine the correlation between RKIP expression and clinicopathologic features in NSCLC patients.
Summary:
- RKIP expression was significantly decreased in NSCLC tissues compared to adjacent normal tissues.
- Reduced RKIP expression was associated with poor differentiation, advanced tumor-node-metastasis (TNM) stage, shorter survival, and lymph node invasion in NSCLC.
- No significant association was found between RKIP expression and gender, age, smoking status, tumor size, or histological type.
Impact:
- RKIP deficiency is linked to NSCLC carcinogenesis and metastasis, suggesting its potential as a biomarker.
- Targeting RKIP may offer a novel therapeutic strategy for managing NSCLC.
More Related Videos
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
The Ras Gene
Ras is a superfamily...
Regulation of Angiogenesis and Blood Supply